Loading
A phase 1 trial of Capecitabine and Doxifluridine in Hepatocellular carcinoma and Metastatic cancer, run by Northwestern University, completed.
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases is a phase 1 interventional study registered as NCT00858429 by Northwestern University, with 18 participants recorded, started 2009-04-01 and reaching its primary completion in 2014-03-19. Interventions recorded: capecitabine, yttrium Y 90 glass microspheres. Conditions recorded: Liver Cancer, Metastatic Cancer.
Linked to the drug Doxifluridine because the registry names it among its interventions and Hepatocellular carcinoma and Metastatic cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/